January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Dr. Sue Currie, Chief Operating Officer at Virion Therapeutics, will speak at the ACCESS ASIA BD Forum @ JPM 2026.
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners. Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities. View more information at: https://biotochina.org/
About Virion Therapeutics
Virion Therapeutics, LLC is a clinical-stage company developing novel immunotherapies that utilize proprietary checkpoint modifiers to enhance/restore, broaden, and elicit sustained immune responses, with the goal to cure cancer and chronic infectious diseases. Virion has since developed a robust pipeline, including its lead VRON-0200 clinical program, and several additional IND-enabling programs, such as its VRON-0300 oncology program for advanced solid tumors, leveraging its proprietary platform technologies.
Virion’s Lead Clinical Program, VRON-0200, for HBV Functional Cure, with sites in Hong Kong and New Zealand, recently presented data at the global liver meeting (AASLD), showing that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy, induced HBV-specific immune activation, restoration, and HBsAg declines, that were sustained and/or continued up to one-year post dosing, in the majority of chronically HBV-infected treated patients. This novel and exciting approach, where a patient’s own immune response is “sparked” (i.e. primed) with VRON-0200, and then “fanned” (aka boosted) by the removal of the HBV virus, position VRON-0200 to be the foundational backbone agent for new combination therapies that could produce meaningful Functional Cure rates for the almost 260 million persons living with chronic HBV worldwide.
About the speaker
Dr. Sue Currie serves as Chief Operating Officer of Virion Therapeutics, LLC, where she and the Company continue to pursue a safe, convenient, accessible, and effective treatment for functional cure for chronic hepatitis B for the 300+ million persons affected by this disease. Virion’s platform technologies, and pipeline, that includes IND-enabling activities for their lead cancer program, offer a novel checkpoint modifier containing mechanism to help restore a patient’s own immune response against cancer and chronic infection.
Sue has 20+ years of strategic, clinical, and scientific leadership, not only within biotechnology and different pharm companies, but also in Veterans Health Administration, academic, correctional health, and community care settings. Additionally, Sue has authored numerous pivotal scientific publications in immuno-oncology and infectious diseases and is a Biotech Leader in the field.
About ACCESS ASIA BD Forum @ JPM 2026
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
Conference Name: ACCESS ASIA BD Forum @ JPM 2026
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/
BioToChina.org 